Beiersdorf leans on Eucerin and derma innovation as Nivea is repositioned — 2025 results and the roadmap for 2026

Table of Contents

  1. Key Highlights:
  2. Introduction
  3. Derma division powers growth: Eucerin, Thiamidol and epigenetics take center stage
  4. Nivea’s plateau: causes, consequences and the rebalancing plan
  5. Luxury segment: La Prairie’s volatility and the role of e‑commerce
  6. Regional dynamics: China, the US, travel retail and emerging markets
  7. Financial snapshot: sales, margins and the conservative 2026 stance
  8. Innovation pipeline and what ‘rebalancing’ practically entails
  9. What the 2026 environment means for investors, retailers and consumers
  10. Industry context: where Beiersdorf’s strategy sits among peers
  11. Execution risks and the levers for 2026–27
  12. Strategic scenarios: potential outcomes depending on execution
  13. Practical measures Beiersdorf can take now
  14. What to watch in 2026
  15. FAQ

Key Highlights:

  • Beiersdorf reported €9.9bn in organic group sales for 2025, up 2.4%, with the derma and health care divisions driving performance—derma grew 11.7% and health care 9.3%.
  • Nivea, the company’s core mass-market brand, stagnated (0.9% growth), prompting a strategic rebalancing emphasizing accessible face care, portfolio broadening across categories, and greater local market autonomy.
  • The company warns of a slower 2026, citing retail and travel‑retail disruptions, raw material and FX pressures, and limited early‑year innovation impact; Beiersdorf expects consumer business sales to be flat to slightly growing on an organic basis.

Introduction

Beiersdorf closed 2025 with modest top‑line growth but a distinct split in performance across its portfolio. The company’s derma brands — notably Eucerin and Aquaphor — delivered double‑digit expansion once again, driven by ingredient‑led innovation and stronger penetration in emerging markets. At the same time, Nivea’s progress slowed and La Prairie continued to face headwinds in the luxury segment. Management has responded by recalibrating Nivea’s strategy and signaling a cautious outlook for 2026 as supply‑chain costs, foreign exchange headwinds and retail disruptions bite into margins.

The outcome matters beyond Beiersdorf’s balance sheet. It surfaces a larger question for consumer beauty firms: which segments sustain growth when mass‑market skin care softens, and how should global champions balance global platforms with granular, market‑level execution? Beiersdorf’s choices — leaning into dermatological efficacy, scaling hero ingredients, and granting markets more autonomy — illustrate one path forward.

Derma division powers growth: Eucerin, Thiamidol and epigenetics take center stage

Beiersdorf’s derma arm recorded its fifth consecutive year of double‑digit growth in 2025, a run that underlines dermatological efficacy as a resilient axis in skin care. Organic sales in the consumer business rose 2.5% to €8.2bn, with the derma and health care divisions delivering the strongest contributions (11.7% and 9.3% respectively). These results reflect both product innovation and disciplined execution in distribution and marketing.

Two technical pillars drove the derma momentum:

  • Thiamidol: This proprietary molecule, developed and marketed across Beiersdorf’s derma franchises, has become a scalable asset. Initially positioned for hyperpigmentation, Thiamidol’s regional rollouts into the US and China enlarged the addressable market and tapped unmet demand for clinically supported pigmentation treatments. The ingredient’s expansion mirrors how patentable actives can be leveraged across brands and geographies to create repeated innovation cycles.
  • Epigenetics serum: Launched under Eucerin and Nivea’s longevity initiatives, epigenetics‑focused formulations capitalized on both scientific narrative and demonstrable claims. The Eucerin Epigenetics Serum positioned the derma range in a premium but accessible niche, merging dermatology credibility with lifestyle appeal.

Eucerin and Aquaphor both benefited from this strategy. Eucerin’s clinical positioning and Aquaphor’s heritage as a skin‑repair staple gave Beiersdorf a multi‑pronged approach: treatable conditions, everyday barrier repair and targeted concerns such as pigmentation. Emerging markets were particularly important. Penetration gains in Southeast Asia, parts of Latin America and greater China drove volume and filled gaps left by slower growth in mature markets.

Real‑world parallel: Across the industry, brands that can combine clinical validation with broad accessibility—those with demonstrable actives and clear consumer guidance—have sustained growth even when the mass market slows. This has been visible in the proliferation of dermocosmetic brands in drugstore and e‑commerce channels globally.

Nivea’s plateau: causes, consequences and the rebalancing plan

Nivea, historically Beiersdorf’s growth engine and flagship in the mass market, grew just 0.9% in 2025. The performance reflects several intersecting pressures: a marked slowdown in global skin care demand, a need to reposition the brand in China, and a timing mismatch between product rollouts and market windows for growth.

The company attributes the softness to:

  • A tougher mass‑market environment. Consumers traded down across discretionary categories and cut back on non‑essential single‑use or high‑frequency purchases, reducing velocity in some mass channels.
  • China’s required repositioning. Nivea faced competitive and structural shifts in Greater China. Beiersdorf completed a Chinese restructuring in Q3 of 2025; the brand returned to double‑digit growth in China in Q4 after those changes.
  • Innovation timing. Nivea concentrated its major innovations toward the latter part of 2025. The brand’s largest ever launch — Nivea Cellular Epigenetics Rejuvenating Serum — arrived in September, meaning most of the year saw limited innovation contribution to revenues.

Management responded by launching a multi‑year rebalancing of the Nivea portfolio, focused on three strategic priorities:

  1. Broaden Nivea’s footprint across face care, body care and deodorants to create a more balanced revenue mix.
  2. Prioritize “accessible” face care propositions — products with strong efficacy at lower price points that can deliver repeat purchase and improve penetration.
  3. Empower local champions: Give priority markets greater scope to adapt portfolios and go‑to‑market strategies to regional consumer needs, specifically naming China, the US, India, Japan and Brazil.

What does that mean in practice? Expect a shift in budget allocation and product planning. Portfolio broadening implies introducing new SKUs and potentially consolidating underperforming variants. Ending the reliance on a few seasonal or promotional spikes requires a steadier cadence of accessible, claim‑driven product launches. Local champions will get more freedom to calibrate assortments and marketing messages to regional channels such as China’s social commerce, India’s modern trade and Brazil’s retail mix.

The recalibration will not be quick. Management said adjustments to innovation pipelines and marketing investments will continue through 2026 and 2027, indicating a multi‑year horizon to restore momentum.

Luxury segment: La Prairie’s volatility and the role of e‑commerce

La Prairie, Beiersdorf’s high‑end luxury line, declined 4.5% in 2025. That performance reflects broader volatility in prestige skin care. Post‑pandemic dynamics have accelerated segmentation between affordable clinical brands and aspirational luxury lines. Consumers who trade up do so selectively, and economic strain or shifting priorities can quickly dampen demand for the highest price tiers.

Still, there were encouraging signs. La Prairie’s Q4 sales in China grew 3.8% sequentially after repositioning efforts and an improved market, and the brand saw positive momentum from new product introductions and e‑commerce. These points illustrate two durable themes for luxury beauty:

  • New launches matter. Exceptionally executed limited editions and hero SKUs can reignite interest in luxury cohorts and justify price premiums when supported by storytelling and channel exclusivity.
  • Digital commerce is non‑negotiable. Luxury brands that marry premium positioning with seamless e‑commerce experiences and personalized digital services gain resilience in fluctuating retail landscapes.

La Prairie’s trajectory shows how luxury names must combine product scarcity, high‑quality execution and omnichannel storytelling to regain stable growth.

Regional dynamics: China, the US, travel retail and emerging markets

Geography drove much of Beiersdorf’s 2025 narrative. While all markets contributed to derma growth, emerging markets were singled out as key drivers. Regional performance varied across brands and channels.

China China demanded strategic attention. The Nivea portfolio required repositioning to meet local tastes and channel behaviors; the completed restructuring in Q3 led to a return to double‑digit growth in Q4 for Nivea in that market. For La Prairie, China also showed sequential improvement. The takeaway: China’s market dynamics reward nimble local execution, faster assortment adaptation and purposeful marketing investment in social commerce and travel retail.

United States Beiersdorf noted disruptions in the US retail landscape that affected the first quarter of 2026 outlook. These disruptions reflect a combination of retailer assortment changes, promotional cadence shifts and the complexity of selling across mass, drugstore and prestige channels. The US remains a priority market, but success requires tailored strategies across channel tiers.

Travel retail Global travel retail remains volatile. Travel patterns have recovered unevenly since the pandemic, and travel retail stakeholders are still reconfiguring assortments and vendor relationships. Beiersdorf cited disruptions in China travel retail specifically as a factor in the early 2026 outlook. Brands dependent on duty‑free and airport distribution must adapt to slower pent‑up travel recovery in certain corridors and compete for increasingly curated shelf space.

Emerging markets Emerging markets delivered outsized derma growth. Lower penetration but fast adoption of clinically effective, accessible products created opportunity. Brands that invest in medical or pharmacist channels, educate local consumers and offer value propositions that align with local skincare priorities—such as pigmentation, barrier repair or sun protection—saw traction.

Financial snapshot: sales, margins and the conservative 2026 stance

Beiersdorf reported organic group sales of €9.9bn for 2025, a 2.4% increase year‑on‑year. The consumer business reported €8.2bn in organic sales, a 2.5% rise. These topline figures mask divergent brand performance: derma and health care led growth, Nivea stagnated, and La Prairie declined.

Management’s 2026 guidance is cautious:

  • Consumer business net sales: expected to be flat to slightly growing on an organic basis, with ongoing volatility and cautious consumer demand.
  • Q1 2026: expected to be below the full‑year range, affected by disruptions in US retail, China travel retail and a reduced innovation impact at Nivea early in the year.
  • EBIT margin from ongoing operations (excluding special factors): expected to be slightly below the prior year’s level. Margin compression drivers include raw material cost increases, unfavorable foreign exchange and limited fixed cost leverage on gross margin, while Beiersdorf plans to maintain strong marketing support.

Management framed this stance as prudent, balancing conservative near‑term visibility with continued investment in innovation and marketing to protect long‑term brand health. CEO Vincent Warnery stressed that the company’s derma and health care strength, a robust pipeline and disciplined execution provide a solid foundation to deliver sustainable growth despite market conditions.

Innovation pipeline and what ‘rebalancing’ practically entails

Beiersdorf’s 2025 results demonstrate a strategic tilt toward ingredient and science‑led innovation. The company emphasized global innovation platforms while giving key markets leeway to localize execution.

Key components of the pipeline and rebalancing include:

  • Hero actives as growth engines: Thiamidol’s scalability across product categories and markets shows how a single active can drive multiple launches and incremental gains. Expect Beiersdorf to replicate that model by protecting IP, broadening claims and creating adjacent SKUs (e.g., serums, spot treatments, daily maintenance products).
  • Calendar management: Concentrating major launches late in the year limited 2025 impact. Beiersdorf must now shift toward a more even cadence of launches so that innovation contributes consistently across quarters. This will require adjustments to R&D timetables, regulatory submissions and marketing plans.
  • Market customization: Local champions will be empowered to tailor SKUs, price points and campaigns. That may result in differentiated product versions for China versus Europe or the US, faster time to market for region‑specific SKUs, and more targeted use of local influencers and retail partnerships.
  • Pricing and accessibility: The push into “accessible face care” suggests Beiersdorf will design products with simplified formulas, focused claims and price points that target mass affluence. These products need to deliver visible benefits while maintaining margin economics through optimized formulations and packaging.
  • Marketing mix reallocation: Rebalancing will involve shifting spend toward channels and messages that deliver the best ROI. For Nivea, that may mean more tactical investment in hero face care items and shopper marketing in high‑traffic channels rather than broad brand branding that dilutes spend effectiveness.

What the 2026 environment means for investors, retailers and consumers

Investors Beiersdorf’s growth split will prompt scrutiny. Derma and health care strength provides a defensive growth pillar, but Nivea’s plateau and La Prairie’s weakness create headline risk. The conservative 2026 guidance, combined with margin pressure, suggests cautious near‑term returns. Investors should monitor:

  • Execution of the Nivea rebalancing (timing, SKU rationalization and regional execution).
  • Derma margin sustainability as product expansion scales and marketing investments maintain share.
  • FX trends and raw material trajectories that will pressure margins if unfavorable.

Retailers Retail partners face a recalibrated assortment from Beiersdorf. Expect an uptick in derma offerings, more focused face care ranges with clear hero products, and potential SKU rationalization in mass channels. Retailers will need to:

  • Reassess planograms to highlight claim‑driven, clinically validated SKUs.
  • Work with Beiersdorf to optimize promotions and avoid margin‑eroding discounting while maintaining footfall.
  • Embrace omnichannel activations for La Prairie and digital conversion tools for Nivea’s accessible face care.

Consumers For shoppers, the immediate impact may be an expanded slate of clinically credible, affordable face care options from Nivea and the continued availability of specialized derma treatments from Eucerin. Consumers in China and other priority markets may see more localized Nivea assortments and targeted messaging. Luxury shoppers will find La Prairie focused on fewer, higher‑impact premium launches and enhanced e‑commerce service.

Industry context: where Beiersdorf’s strategy sits among peers

Beiersdorf’s pivot towards dermocosmetics and local market empowerment mirrors a broader industry trend: consumers are increasingly prioritizing efficacy and clear claims. Derma brands within large beauty groups have gained share over generalist mass‑market labels during demand slowdowns because they offer perceived value through outcomes and repeat usage. Companies that blend clinical claims with accessible price points have often outperformed pure commodity mass brands.

At the same time, luxury brands must navigate a bifurcated consumer base. The highest tier of prestige retains strong aspiration value for a subset of affluent consumers, but broad luxury growth is sensitive to macroeconomic swings. This dynamic explains La Prairie’s mixed performance—structural brand strength offset by weak discretionary spending in some regions.

Beiersdorf’s decision to delegate more authority to markets is consistent with rising evidence that global platforms must be tailored locally. Chinese social commerce, for example, rewards lightning‑fast campaign execution and influencer-driven SKUs. Markets that centralize decisions risk missing local nuance and timing.

Execution risks and the levers for 2026–27

Beiersdorf’s roadmap contains clear levers for success and identifiable risks.

Levers:

  • Scale derma actives globally: Expand Thiamidol and other proven actives into new categories and geographies.
  • Calibrate launch cadence: Stagger launches to provide revenue drivers across quarters.
  • Local market autonomy: Empower markets that demonstrate high growth potential to test and scale innovations.
  • Cargo and channel optimization: Reconfigure travel retail and distributor strategies to adapt to slower traffic and changing assortments.

Risks:

  • Raw material inflation and supply bottlenecks: Persistent input cost increases will compress gross margins unless offset by pricing or efficiency.
  • Foreign exchange volatility: An unfavorable FX environment can erode reported revenues and margins, particularly for a firm with significant exposure to multiple currencies.
  • Retail disruption: Continued evolution in the US retail landscape and uneven travel retail recovery could depress volumes and complicate inventory planning.
  • Innovation execution: Delays in product registrations, manufacturing scale‑up or poor launch execution can undercut revenue expectations—lessons Beiersdorf learned from a concentrated late‑year innovation schedule in 2025.

Operational teams will need to balance near‑term margin protection with the long‑term imperative to invest in the pipeline and channel partnerships. That balancing act will determine whether the company transitions from a defensive posture in 2026 to consistent growth beyond 2027.

Strategic scenarios: potential outcomes depending on execution

Scenario A — Successful rebalancing and steady recovery If Beiersdorf executes the Nivea rebalancing effectively, staggers launches across 2026, and scales Thiamidol and epigenetics products into new regions, the company can offset margin pressures with volume growth and gradual price management. Under this scenario, derma remains the growth engine, Nivea stabilizes and La Prairie regains momentum through targeted launches and digital conversion, producing a return to mid‑single digit organic growth by late 2026/2027.

Scenario B — Structural slow growth and margin squeeze If raw material costs and FX continue to bite and innovation execution remains uneven, Beiersdorf could face sluggish topline growth and eroding margins. Nivea’s repositioning might take longer than expected to show results, and La Prairie could continue to underperform. Management could respond with cost cuts or slower marketing investment, which risks undermining long‑term brand health.

Scenario C — Opportunity from accelerated derma success Failure or delay in Nivea recovery might push the company to double down on derma, accelerating investments in clinical marketing, pharmacy channels and e‑commerce for Eucerin and related brands. That could produce outsized near‑term growth but also risk overdependence on a single segment, making broader portfolio diversification a secondary priority.

Beiersdorf’s stated path suggests management prefers Scenario A: achieve balanced recovery while retaining capacity to invest in derma and health care.

Practical measures Beiersdorf can take now

To align operations with strategy and market realities, several practical measures would be logical:

  • Smoother product launch calendar: Shift development and regulatory resources to ensure new SKUs are spread throughout the year.
  • SKU rationalization: Remove low‑performing variants to focus on high‑velocity SKUs and free up marketing funds.
  • Localized go‑to‑market pilots: Scale successful local pilots across other similar markets to rapidly capture share.
  • Margin management: Negotiate supplier contracts, optimize pack sizes and explore formula simplifications to reduce raw material exposure without degrading consumer perception of efficacy.
  • Channel‑specific strategies: Strengthen pharmacy partnerships for derma brands, optimize mass promotions for Nivea’s accessible face care, and increase DTC and marketplace investments for La Prairie.

These actions reduce near‑term cost and complexity while enabling focused investments where returns are most visible.

What to watch in 2026

Investors and industry observers should monitor a handful of indicators that will reveal whether Beiersdorf’s strategy is translating into results:

  • Quarterly sales mix by brand: Check if derma continues to outpace mass and whether Nivea’s face care gains accelerate.
  • Innovation cadence and contribution: Track the percentage of sales attributable to new launches and the timing of major releases.
  • Regional growth rates: China and other priority markets’ performance will be early signals of successful local adaptation.
  • Margin trajectory: EBIT margin progression will indicate whether cost pressures and FX are being managed effectively.
  • Retail channel performance: Watch duty‑free, e‑commerce and drugstore channels for signs of volume shifts.

If Beiersdorf can convert derma momentum into diversified growth and restore Nivea’s commercial energy, it will demonstrate that a dual strategy—science‑led global platforms plus empowered local execution—remains viable in a softer skin care market.

FAQ

Q: What were Beiersdorf’s main financial results for 2025? A: Group organic sales reached €9.9bn in 2025, up 2.4% year‑on‑year. The consumer business grew organically by 2.5% to €8.2bn. The derma division rose 11.7% and health care 9.3%. Nivea grew 0.9% and La Prairie declined 4.5%.

Q: Why did Nivea’s growth slow in 2025? A: Nivea faced a soft mass‑market environment, required repositioning in China, and concentrated its major innovations late in the year, limiting the contribution of new launches to annual sales.

Q: What is Beiersdorf’s rebalancing strategy for Nivea? A: The strategy focuses on three priorities: broaden Nivea’s portfolio across face care, body care and deodorants; prioritize accessible face care propositions; and empower local markets such as China, the US, India, Japan and Brazil to adapt portfolios and execution.

Q: Which Beiersdorf segment showed the strongest performance and why? A: The derma segment showed the strongest performance, growing 11.7%. Growth was driven by product innovation (notably Thiamidol and epigenetics serums), expansion into new regions including the US and China, and strong adoption in emerging markets.

Q: How did La Prairie perform and what were the dynamics behind it? A: La Prairie was down 4.5% in 2025. The brand faced a volatile luxury market, but sequential improvements were visible in China (Q4 up 3.8%) and from e‑commerce strength and new product launches.

Q: What does Beiersdorf expect for 2026? A: The company expects consumer business net sales to be flat to slightly growing on an organic basis, with continued volatility and cautious consumer demand. Q1 2026 is expected to be below the full‑year range. The EBIT margin for the consumer business is expected to be slightly below the prior year, due to raw material cost increases, unfavorable FX and limited fixed cost leverage, while marketing support will remain strong.

Q: What are the main risks facing Beiersdorf? A: Key risks include continued raw material inflation, foreign exchange headwinds, retail and travel retail disruptions, uneven innovation impact due to launch timing, and potential delays in local market execution.

Q: How does Beiersdorf’s approach compare with industry peers? A: Beiersdorf’s focus on dermocosmetic efficacy and localized execution aligns with broader industry trends emphasizing clinically proven actives and market agility. The company’s dual focus—global innovation platforms supported by regional autonomy—matches approaches adopted by other major beauty groups seeking to balance scale with local relevance.

Q: What will be the impact on consumers and retail channels? A: Consumers should see more clinically credible, accessible face care options from Nivea and continued specialty offerings from derma brands like Eucerin. Retailers will encounter a refined assortment emphasizing claim‑driven SKUs and may collaborate more closely with Beiersdorf on targeted activations and omnichannel strategies.

Q: How long will the rebalancing and adjustments take? A: Beiersdorf indicated recalibration will continue through 2026 and 2027, suggesting a multi‑year process to fully integrate portfolio changes, innovation cadence adjustments and marketing reallocation.

Q: Can derma growth offset Nivea’s slowdown? A: Derma growth provides a powerful offset and reduces reliance on mass channels, but full portfolio resilience depends on whether Nivea can be restored to stable growth and whether La Prairie’s luxury performance rebounds. The company’s ability to scale derma without sacrificing Nivea’s market share will determine overall success.

Q: Where should investors look for signs of recovery? A: Investors should watch quarterly brand contributions, the revenue share from new launches, regional growth in China and the US, margin trends, and the company’s ability to manage raw material and FX pressures.

Beiersdorf’s 2025 results tell a nuanced story: strong, repeatable gains in dermatological skin care and health care, counterbalanced by mass‑market softness and luxury volatility. Management’s response — rebalancing Nivea, doubling down on derma actives and giving markets more autonomy — is a pragmatic approach to a market that rewards both scientific credibility and local agility. Whether the company can translate that strategy into sustainable growth will depend on execution over the next 18–24 months, the trajectory of input costs and currency moves, and the pace at which consumer demand stabilizes across key markets.